Bryan

List of Publications by Year
in descending order

55 papers	2,399 citations	304602 22 h-index	223716 46 g-index
55 all docs	55 docs citations	55 times ranked	3576 citing authors

#	Article	IF	Citations
1	Commentary: Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment. Neurosurgery, 2021, 89, E68-E69.	0.6	1
2	Neurophysiologic Mapping of Thalamocortical Tract in Asleep Craniotomies: Promising Results From an Early Experience. Operative Neurosurgery, 2021, 20, 219-225.	0.4	5
3	Commentary: The Glioma-Network Interface: A Review of the Relationship Between Glioma Molecular Subtype and Intratumoral Function. Neurosurgery, 2021, 88, E273-E274.	0.6	0
4	Rational Chemical and Genetic Modifications Enhance Avidity and Function of CD70-Directed CAR-T-Cells for Myeloid Leukemia. Blood, 2021, 138, 405-405.	0.6	1
5	A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq. Molecular Therapy, 2020, 28, 2577-2592.	3.7	58
6	Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. Expert Review of Clinical Pharmacology, 2020, 13, 1147-1158.	1.3	8
7	IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice. OncoImmunology, 2020, 9, 1806662.	2.1	26
8	Survival After Surgery for Renal Cell Carcinoma Metastatic to the Spine: Impact of Modern Systemic Therapies on Outcomes. Neurosurgery, 2020, 87, 1174-1180.	0.6	10
9	A Common Rule for Resection of Glioblastoma in the Molecular Era. JAMA Oncology, 2020, 6, 503.	3.4	3
10	Receptor tyrosine kinase gene amplification is predictive of intraoperative seizures during glioma resection with functional mapping. Journal of Neurosurgery, 2020, 132, 1017-1023.	0.9	5
11	CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nature Biotechnology, 2019, 37, 1049-1058.	9.4	347
12	A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibition. OncoImmunology, 2019, 8, e1678921.	2.1	18
13	Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Advances, 2019, 3, 3248-3260.	2.5	76
14	CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. , 2019, 7, 304.		181
15	Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19. Clinical Cancer Research, 2019, 25, 7046-7057.	3.2	56
16	Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. Clinical Cancer Research, 2019, 25, 2042-2048.	3.2	77
17	Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts. Clinical Cancer Research, 2019, 25, 358-368.	3.2	51
18	Use of CD70 Targeted Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML). Blood, 2019, 134, 4443-4443.	0.6	6

#	Article	IF	Citations
19	Implication of Biomarker Mutations for Predicting Survival in Patients With Metastatic Lung Cancer to the Spine. Spine, 2018, 43, E1274-E1280.	1.0	7
20	Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma. OncoImmunology, 2018, 7, e1434464.	2.1	69
21	A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma. Clinical Cancer Research, 2018, 24, 3611-3631.	3.2	39
22	Rare Giant Prevertebral Thoracic Myelomeningocele. World Neurosurgery, 2018, 109, 296-297.	0.7	2
23	Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons. Neurosurgical Focus, 2018, 44, E13.	1.0	25
24	Sporadic NF2 Mosaic: Multiple spinal schwannomas presenting with severe, intractable pain following pregnancy. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 2017, 10, 142-145.	0.2	0
25	Effect of Immunotherapy Status on Outcomes in Patients With Metastatic Melanoma to the Spine. Spine, 2017, 42, E721-E725.	1.0	11
26	Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. Cancer Immunology, Immunotherapy, 2016, 65, 205-211.	2.0	6
27	Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection. Current Opinion in Virology, 2015, 13, 25-32.	2.6	19
28	Editorial: Not everything that matters can be measured and not everything that can be measured matters. Journal of Neurosurgery, 2015, 123, 543-546.	0.9	3
29	Are BiTEs the â€œmissing linkâ€•in cancer therapy?. OncoImmunology, 2015, 4, e1008339.	2.1	59
30	EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma. PLoS ONE, 2014, 9, e94281.	1.1	99
31	Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy. OncoImmunology, 2014, 3, e944054.	2.1	19
32	Reply. Plastic and Reconstructive Surgery, 2014, 134, 667e-668e.	0.7	3
33	Impact of PhD training on scholarship in a neurosurgical career. Journal of Neurosurgery, 2014, 120, 730-735.	0.9	29
34	EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss. Clinical Cancer Research, 2014, 20, 972-984.	3.2	254
35	Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. Journal of Clinical Neuroscience, 2014, 21, 189-190.	0.8	94
36	Factors Influencing Fellowship Selection, Career Trajectory, and Academic Productivity among Plastic Surgeons. Plastic and Reconstructive Surgery, 2014, 133, 730-736.	0.7	89

#	Article	IF	Citations
37	Response. Journal of Neurosurgery, 2014, 120, 728-9.	0.9	0
38	An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. Expert Review of Clinical Pharmacology, 2013, 6, 375-386.	1.3	20
39	BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. Cancer Immunology, Immunotherapy, 2013, 62, 983-987.	2.0	13
40	Human Regulatory T Cells Kill Tumor Cells through Granzyme-Dependent Cytotoxicity upon Retargeting with a Bispecific Antibody. Cancer Immunology Research, 2013, 1, 163-167.	1.6	61
41	Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis. Journal of Immunological Methods, 2013, 395, 14-20.	0.6	5
42	Isocitrate dehydrogenase 1: what it means to the neurosurgeon. Journal of Neurosurgery, 2013, 118, 1176-1180.	0.9	20
43	A novel bispecific antibody recruits T cells to eradicate tumors in the â€œimmunologically privilegedâ€• central nervous system. OncoImmunology, 2013, 2, e23639.	2.1	16
44	Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody. OncoImmunology, 2013, 2, e26757.	2.1	30
45	Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 270-275.	3.3	120
46	Myeloablative Temozolomide Enhances CD8+ T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice. PLoS ONE, 2013, 8, e59082.	1.1	56
47	Rindopepimut. Drugs of the Future, 2013, 38, 147.	0.0	19
48	Inflammatory Pseudotumor of the Lateral Ventricle in a Pediatric Patient. Pediatric Neurosurgery, 2012, 48, 374-378.	0.4	1
49	Regulatory T Cells Move in When Gliomas Say â€œI DOâ€• Clinical Cancer Research, 2012, 18, 6086-6088.	3.2	11
50	Enzyme redesign guided by cancer-derived IDH1 mutations. Nature Chemical Biology, 2012, 8, 887-889.	3.9	22
51	Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas. Current Drug Discovery Technologies, 2012, 9, 237-255.	0.6	4
52	Convection Enhanced Delivery of Macromolecules for Brain Tumors. Current Drug Discovery Technologies, 2012, 9, 305-310.	0.6	29
53	Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opinion on Biological Therapy, 2011, 11, 843-853.	1.4	78
54	Imaging of Convection Enhanced Delivery of Toxins in Humans. Toxins, 2011, 3, 201-206.	1.5	20

#	Article	IF	Citations
55	EGFRvIIIâ€Targeted Vaccination Therapy of Malignant Glioma. Brain Pathology, 2009, 19, 713-723.	2.1	118